While multiple groups have investigated the prognostic role of genomic and immunologic biomarker signatures in early stage NSCLC, Muley et al. demonstrated a relatively straightforward combination of presurgery CEA and CYFRA-21 levels can be prognostic for relapse-free survival in this patient cohort of stage I-IIIA patients [39]. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.